NASDAQ:HSGX - Histogenics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.12 -0.01 (-7.65 %)
(As of 03/22/2019 04:00 PM ET)
Previous Close$0.1208
Today's Range$0.12 - $0.1290
52-Week Range$0.08 - $3.05
Volume6.01 million shs
Average Volume7.35 million shs
Market Capitalization$7.49 million
P/E Ratio-0.12
Dividend YieldN/A
Beta3.52
Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee. It has an exclusive channel collaboration agreement with Intrexon Corporation for the development and commercialization of allogeneic genetically modified chondrocyte cell therapeutics for the treatment or repair of damaged articular hyaline cartilage in humans. Histogenics Corporation was founded in 2000 and is headquartered in Waltham, Massachusetts.

Receive HSGX News and Ratings via Email

Sign-up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HSGX
CUSIPN/A
Phone781-547-7900

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.46) per share

Profitability

Net Income$-26,410,000.00

Miscellaneous

Employees45
Market Cap$7.49 million
Next Earnings DateN/A
OptionableNot Optionable

Histogenics (NASDAQ:HSGX) Frequently Asked Questions

What is Histogenics' stock symbol?

Histogenics trades on the NASDAQ under the ticker symbol "HSGX."

How were Histogenics' earnings last quarter?

Histogenics Corp (NASDAQ:HSGX) issued its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.23) by $0.10. View Histogenics' Earnings History.

What price target have analysts set for HSGX?

4 analysts have issued 1 year target prices for Histogenics' shares. Their forecasts range from $1.00 to $5.00. On average, they anticipate Histogenics' stock price to reach $3.1667 in the next year. This suggests a possible upside of 2,521.4% from the stock's current price. View Analyst Price Targets for Histogenics.

What is the consensus analysts' recommendation for Histogenics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Histogenics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Histogenics.

What are Wall Street analysts saying about Histogenics stock?

Here are some recent quotes from research analysts about Histogenics stock:
  • 1. According to Zacks Investment Research, "Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts. " (1/15/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our price target of $21/share is based on an equally-weighted composite of: (a) $12.6/share, as a 35x multiple of taxed and diluted $3.85 discounted back to FY19 at 20% (in line with the expected PE multiple and discount rate of an early development-stage biotechnology company); and (b) an NPV of $29.3/ share (discounted cash flow analysis using a 12% discount rate and 3.5% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company). Translate Bio, Inc." (12/24/2018)

Has Histogenics been receiving favorable news coverage?

News coverage about HSGX stock has trended somewhat positive this week, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Histogenics earned a media sentiment score of 0.6 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future.

Are investors shorting Histogenics?

Histogenics saw a decrease in short interest in the month of February. As of February 28th, there was short interest totalling 411,801 shares, a decrease of 84.3% from the February 15th total of 2,631,096 shares. Based on an average trading volume of 3,856,960 shares, the short-interest ratio is currently 0.1 days. Currently, 0.8% of the company's stock are sold short. View Histogenics' Current Options Chain.

Who are some of Histogenics' key competitors?

What other stocks do shareholders of Histogenics own?

Who are Histogenics' key executives?

Histogenics' management team includes the folowing people:
  • Mr. Adam D. Gridley, Pres, CEO, Treasurer, Sec. & Director (Age 47)
  • Mr. Jonathan I. Lieber, Interim Chief Financial Officer (Age 49)
  • Mr. Stephen R. Kennedy, Exec. VP & COO (Age 62)

When did Histogenics IPO?

(HSGX) raised $60 million in an IPO on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

Who are Histogenics' major shareholders?

Histogenics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.47%) and Geode Capital Management LLC (0.47%). Company insiders that own Histogenics stock include Adam Gridley, David N Gill and Randal J Kirk. View Institutional Ownership Trends for Histogenics.

Which institutional investors are buying Histogenics stock?

HSGX stock was bought by a variety of institutional investors in the last quarter, including Geode Capital Management LLC and Geode Capital Management LLC. Company insiders that have bought Histogenics stock in the last two years include Adam Gridley and David N Gill. View Insider Buying and Selling for Histogenics.

How do I buy shares of Histogenics?

Shares of HSGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Histogenics' stock price today?

One share of HSGX stock can currently be purchased for approximately $0.1208.

How big of a company is Histogenics?

Histogenics has a market capitalization of $7.49 million. The biotechnology company earns $-26,410,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Histogenics employs 45 workers across the globe.

What is Histogenics' official website?

The official website for Histogenics is http://www.histogenics.com.

How can I contact Histogenics?

Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]


MarketBeat Community Rating for Histogenics (NASDAQ HSGX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  228 (Vote Underperform)
Total Votes:  524
MarketBeat's community ratings are surveys of what our community members think about Histogenics and other stocks. Vote "Outperform" if you believe HSGX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSGX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel